Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Vitamin D Induction in Optic Neuritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Canadian residents~* Patients must be between age 18 and 45 years~* Patients must have a diagnosis of either a CIS or RRMS (according to McDonald criteria)~* Patients must have an EDSS of 5.5 or less~* Patients must demonstrate features of a first typical optic neuritis within 21 days of recruitment (or must initiate treatment by day 30)~* Patients must have a baseline 25(OH)D \< 80 nmol/L regardless of vitamin D3 supplementation~* Patients must have no contraindications to high-dose vitamin D supplementation~* Female patients must consent to use a reliable form of contraception (oral contraceptive pill, intrauterine device, barrier methods, abstinence) for the duration of the active treatment phase (first 90 days of where study drug provided) of the trial~* Patients must provide written informed consent.~Exclusion Criteria:~* Patients who have had a previous optic neuritis~* Patients with evidence of a non-inflammatory cause of optic neuropathy~* Patients with evidence of neuromyelitis optica spectrum disorder or NMOSD (i.e. bilateral optic neuritis, MRI evidence of longitudinally enhancing lesions involving the optic nerves (involving three or more segments of the optic nerve), and/or involving the optic chiasm, and optic tracts~* Patients with a 25(OH)D \> 80 nmol/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- High-Dose Vitamin D Treatment Group (Type: EXPERIMENTAL): Patients in this arm will receive:~-5 days of high-dose oral vitamin D3 (50,000 IU daily x 5), followed by 85 days of moderate dose oral vitamin D3 (10,000 IU daily x 85 days)
- Placebo/Standard Vitamin D3 Group (Type: PLACEBO_COMPARATOR): Patients in this arm will receive Placebo/Standard of Care Vitamin D3:~-5 days of placebo, followed by 85 days of standard of care dose of oral vitamin D3 (4,000 IU daily x 85 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).